# IMAGION BIOSYSTEMS LIMITED

(ASX**: IBX**)

26 November 2020

**Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001**

MELBOURNE - Imagion Biosystems Limited (ASX: IBX) (the **Company**) gives notice that, on 18 November 2020 and on 25 November 2020 the Company issued a total of 10,740,000 fully paid ordinary shares (**Shares**) in the Company as the result of shareholders exercising their options in the Company.

The Company issued the above Shares without a disclosure document to investors under Part 6D.2 of the *Corporations Act 2001* (Cth) (**Act**).

***Notice under Section 708A(5)(e) of the Act***

The Company hereby gives notice that:

1. the Company issued the shares without disclosure to investors under Part 6D.2 of the Act;
2. this notice is being given under section 708A(5)(e) of the Act;
3. as at the date of this notice the Company has complied with:
    a. the provisions of Chapter 2M of the Act as they apply to the Company; and
    b. section 674 of the Act; and
4. as at the date of this notice, there is no information that is "excluded information" within the meaning of Sections 708A(7) and 708A(8) of the Act.

**-ENDS**

**About Imagion Biosystems**
Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology. Combining biotechnology and nanotechnology the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.

**This Announcement has been approved by the Board of Imagion Biosystems Limited**

**For further information please visit www.imagionbiosystems.com**

**U.S. Media Contact:**
Matthew Wygant
matthew@biotechwriting.com
+1-408-905-7630

**Australian Media & Investor Relations:**
Kyahn Williamson, WE Communications
We-AUImagionBiosystems@we-worldwide.com
+61-3-9866-4722